Asia Pacific
Refine Search
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Biotechnology
Japanese drug majors Takeda Pharmaceutical and Sumitomo Dainippon Pharma announced today that Takeda will succeed the manufacturing and marketing approval and the marketing rights of Replagal (agalsidase alfa) for Fabry disease, an α-galactosidase enzyme intravenous (IV) infusion, as of February 15, 2022. 26 November 2021
Biosimilars
Japanese mid-size drugmaker Mochida Pharmaceutical and Ayumi Pharmaceutical announced that Adalimumab BS MA (adalimumab biosimilar, code: LBAL) has now been launched in Japan as the NHI (National Health Insurance) drug price has been listed today. 25 November 2021
Biotechnology
Japanese drugmaker Ono Pharmaceutical and its partner Bristol Myers Squibb have announced the approval for the use of Opdivo (nivolumab) in two new indications in Japan. 25 November 2021
Biotechnology
The European Commission (EC) has approved Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy, says Chinese biotech BeiGene. 24 November 2021
Pharmaceutical
Multinationals corporations (MNCs) have been actively adding China to their multicenter global clinical studies in recent years, it was made clear at a recent meeting. 24 November 2021
Biotechnology
French pharma major Sanofi has inked an agreement with Chinese tech giant Baidu, aimed at improving the company’s product design processes. 23 November 2021
Biotechnology
Neurocrine Biosciences and Japanese firm Sosei Heptares have agreed a strategic collaboration and licensing deal to develop muscarinic receptor agonists which the US company will study in schizophrenia, dementia and other neuropsychiatric disorders. 22 November 2021
Biotechnology
SCG Cell Therapy plans to establish Singapore as its international hub for cell therapy research, manufacturing and clinical development to deliver products across Asia Pacific, the USA, Europe and the world. 19 November 2021
Biotechnology
Japanese drugmaker Daiichi Sankyo today announced positive top-line results from the global pivotal QuANTUMFirst Phase III trial evaluating quizartinib, a highly potent and selective FLT3 inhibitor, in patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). 19 November 2021
Biotechnology
China’s biotech industry enjoyed significant growth in the past several years, but major bottlenecks are looming as Chinese biotechs aims for a global expansion, said speakers at the two-day event Chinatrials on November 11 in Shanghai. 17 November 2021
Biotechnology
The neuromyelitis optica spectrum disorder (NMOSD) therapeutics market is highly genericized, with corticosteroids and immunosuppressants currently accounting for the highest portion of prescribed drugs in China. 16 November 2021
Biotechnology
Of the companies developing gene therapies in Japan, Takeda is leading the way, according to data and analytics company GlobalData. 15 November 2021
Biotechnology
Japanese drugmaker Ono Pharmaceutical closed trading today up 2.4% at 2,464 yen, after announcing that it entered into the settlement agreement with Dr Tasuku Honjo to resolve the litigation raised by him regarding the Osaka District Court 2020 (Wa), No 5608 claiming dividends related to the third-party litigation, following the Court settlement recommendation. 12 November 2021
Biotechnology
French rare diseases company Dynacure has entered a long-term strategic development and commercialization agreement with Japanese drugmaker Nippon Shinyaku. 11 November 2021
Biotechnology
Japanese pharma major Chugai Pharmaceutical says it has filed an application with the Ministry of Health, Labor and Welfare (MHLW) for approval of additional indication for the anti-coagulation factor IXa/X humanized bispecific monoclonal antibody/coagulation factor VIII substitute Hemlibra (emicizumab [genetical recombination]) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people with acquired blood coagulation factor VIII deficiency. 11 November 2021
Biosimilars
Chinese biotech Bio Thera Solutions has filed a new drug application (NDA) with China’s National Medical Products Administration (NMPA) to gain approval of what would be the country's first biosimilar of Actemra (tocilizumab). 10 November 2021
Biotechnology
Japanese drugmaker Ono Pharmaceutical has announced its South Korean subsidiary has received a marketing approval for Velexbru (tirabrutinib hydrochloride) tablet 80mg, a Bruton’s tyrosine kinase (BTK) inhibitor, from the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of recurrent or refractory B-cell primary central nervous system lymphoma. 8 November 2021
Pharmaceutical
Mid-sized Japanese drugmaker Nippon Shinyaku, which is focussed on rare disease and blood cancer treatments, has announced the setting up a subsidiary in China’s capital, Beijing. 5 November 2021
Biotechnology
The COVID-19 vaccine developed by US biotech Novavax and its partner the Serum Institute of India (SII) has been granted a regulatory approval for the first time. 2 November 2021
Biotechnology
Japanese biotech start-up Aculys Pharma today announced the closing of a $60 million Series A financing led by SoftBank Vision Fund 2 and joined by Catalys Pacific, HBM Healthcare Investments, Global Founders Capital, Sumitomo Mitsui Trust Investment, and ANRI. 1 November 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze